660842-05-7

Basic information

• Product Name: (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER
• Synonyms: (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER;UKRORGSYN-BB BBV-094563;2-bromo-4-fluoro-1-phenylmethoxybenzene
• CAS NO: 660842-05-7
• Molecular Formula: C₁₃H₁₀BrFO
• Molecular Weight: 544.2253264
• Mol File: 660842-05-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER(660842-05-7)
• EPA Substance Registry System: (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER(660842-05-7)

Safety Data

• Hazardous Substances Data: 660842-05-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2-BROMO-4-FLUOROPHENYL)BENZYL ETHER is used as a building block for the development of various pharmaceutical products. Its unique structure allows it to be a key component in the synthesis of new drugs, contributing to the discovery of innovative treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER is utilized as a fundamental component in the creation of pesticides and other agrochemical products. Its incorporation into these products can enhance their effectiveness and contribute to more sustainable agricultural practices.
Used in Organic Synthesis:
(2-BROMO-4-FLUOROPHENYL)BENZYL ETHER is used as a reagent in chemical reactions to introduce its specific moiety into other organic molecules. This capability makes it a valuable tool in the synthesis of a wide range of organic compounds for various applications.
Used in Drug Discovery and Medicinal Chemistry:
As a significant contributor to the field of drug discovery and medicinal chemistry, (2-BROMO-4-FLUOROPHENYL)BENZYL ETHER serves as a valuable precursor for the synthesis of bioactive compounds. Its unique properties enable researchers to explore new avenues in the development of life-saving medications and therapies.

Upstream product

• 496-69-5 2-bromo-4-fluoro-phenol 
• 100-39-0 benzyl bromide 
• 452-08-4 2-bromo-4-fluoro-1-methoxybenzene 

Downstream Products

• 1238894-70-6 (S)-4-fluoro-2-(2-hydroxypropyl)phenol 
• 1238894-59-1 (R)-(-)-1-[2-(benzyloxy)-5-fluorophenyl]propan-2-yl acetate 
• 1238894-63-7 (S)-(+)-1-[2-(benzyloxy)-5-fluorophenyl]propan-2-ol 
• 1376335-10-2 4-(2-benzyloxy-5-fluoro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1238894-45-5 1-[2-(benzyloxy)-5-fluorophenyl]propan-2-ol 
• 1219443-76-1 2-benzyloxy-5-fluoro-(4'-ethyl)diphenylmethanol 

Relevant articles and documents

MACROCYCLIC KINASE INHIBITOR

Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.

MACROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND USES THEREOF

The present disclosure describes kinases (ALK, ROS1, and TRK) inhibitors and their uses. The pharmaceutical compositions comprising such kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also des

RADIOLABELLED mGluR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

RADIOLABELLED mGLuR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Straightforward synthesis of enantiopure 2,3-dihydrobenzofurans by a sequential stereoselective biotransformation and chemical intramolecular cyclization

(Equation Presented). A new family of optically active 2,3- dihydrobenzofurans has been prepared by a simple chemoenzymatic asymmetric strategy. This synthetic approach is based on the combination of a lipase-mediated kinetic resolution of 1-aryl-2-propanols or bioreduction of the corresponding ketones followed by an intramolecular cyclization reaction. These novel compounds have been prepared in enantiopure form and in good overall yield through a straightforward route.

ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME

There is provided a 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, pa

NOVEL COMPOUNDS

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation